CME Sponsor:
Imedex

Location:
New York Marriott at the Brooklyn Bridge
Brooklyn, New York

Course Chairs :
John M. Kirkwood, MD
University of Pittsburgh Medical Center
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States

Alexander M. M. Eggermont, MD, PhD
Cancer Institute Gustave Roussy
Paris, France

Co-chairs:
Anthony TC Chan, MD, FRCP
The Chinese University of Hong Kong
Hong Kong SAR, People’s Republic of China

Stephen L. Chan, MD
The Chinese University of Hong Kong
Hong Kong SAR, People’s Republic of China

Alex Y. Chang, MD
John Hopkins Singapore International
Medical Centre
Singapore, Singapore

Li-Tzong Chen, MD, PhD
National Institute of Cancer Research,
National Health Research Institutes
Tainan, Taiwan

Ann-Lii, Cheng, MD, PhD
National Taiwan University Hospital
Taipei, Taiwan

Mario Dicato, MD
Luxembourg Medical Center
Luxembourg, Luxembourg

Haruhiro Inoue, MD, PhD
Showa University Northern Yokohama
Hospital Digestive Disease Center
Yokohama, Japan

Hwoon-Yong Jung, MD, PhD, AGAF
Asan Medical Center
University of Ulsan College of Medicine
Seoul, South Korea

Yoon-Koo Kang, MD, PhD
Congress Chair
Asan Medical Center
University of Ulsan College of Medicine
Seoul, South Korea

Jong Hoon Kim, MD, PhD
Asan Medical Center
University of Ulsan College of Medicine
Seoul, South Korea

Song, Chel Kim, MD
Asan Medical Center
University of Ulsan College of Medicine
Songpa-gu, Seoul, South Korea

Tae Won Kim, MD, PhD
Asan Medical Center
University of Ulsan College of Medicine
Seoul, South Korea

Jin Li, MD, PhD
Fudan University Shanghai
Cancer Center
Shanghai, China

Brigette Ma, MBBS, FRACP
The Chinese University of Hong Kong
Hong Kong SAR, People’s Republic of China

Atsushi Ohtsu, MD, PhD
National Cancer Center Hospital East
Kashiwa, Japan

Takuji Okusaka, MD, PhD
National Cancer Center Hospital
Tokyo, Japan

Joong-Won Park, MD, PhD
Center for Liver Cancer National
Cancer Center
Goyang, South Korea

Young Suk Park, MD
Samsung Medical Center
Sungkyunkwan University School of Medicine
Seoul, South Korea

Jinsil Seong, MD, PhD
Yonsei University Medical College
Seoul, South Korea

Aesun Shin, MD, PhD
National Cancer Center
Gyonggi-do, South Korea

Kohei Shitara, MD
Aichi Cancer Center Hospital
Nagoya-shi, Aichi-Ken, Japan

Virote Sriuranpong, MD, PhD
Chulalongkorn University
The Chulalongkorn University and The King Chulalongkorn Memorial Hospital
Bangkok, Thailand

Eric Van Cutsem, MD, PhD
Congress Chair
University Hospital Gasthuisberg
Leuven, Belgium

Han-Kwang Yang, MD, PhD, FACS
Seoul National University Hospital
Seoul, South Korea

Number of Credits:
11.0 AMA PRA Category 1 CreditTM   

Registration:
Early (payment received by 7/19/11) $299.00
Discount (payment received by 9/8/11) $399.00
Regular (payment received after 9/8/11) $499.00
Nurses/Residents/Students (proof of eligibility must accompany) $199.00

For easy registration, feel free to call (512) 708-4678.

Link  

Detailed Description:
This educational activity is specifically designed for dermatologists, oncologists, and other clinicians, physicians-in-training, and health care professionals (nurses, pharmacists, physician assistants, etc.) who are involved and/or interested in the therapeutic management of patients with melanoma.

This Perspectives in Melanoma represents the 15th in this series of premier forums for discussion of the latest advances in melanoma research. It will utilize interactive programming and will host exciting new presentations by the world’s leading investigators, and presentations of new screening and staging modalities, as well as the range of emerging new management approaches, and clinical trial updates.

Objectives:
After successful completion of this course, participants should be able to:
1.    Have increased awareness/knowledge regarding:
       o    New strategies for chemoprevention of melanoma
       o    The role of signal transduction pathways, such as RAF-MEK-ERK, and mutations in genes such as BRAF and NRAS, in melanoma pathogenesis
2.    Have increased confidence in their ability to:
       o    Use new molecular strategies for melanoma screening and diagnosis
       o    Appropriately select, administer, and monitor response to immunotherapies for melanoma
       o    Make appropriate treatment recommendations for various subgroups of melanoma patients, such as those with brain metastases, or those with uveal or mucosal tumors
3.    Increase the frequency (compared with current) with which they plan to:
       o    Use biomarkers and/or mutation status to assist in making treatment decisions for patients with melanoma
       o    Enroll patients in clinical trials of new targeted therapies or immunotherapies